Established models of T-helper-2-cell dominance in BALB/c mice infected with Leishmania
major—involving the early production of interleukin-4 by a small subset of Leishmania …

Leishmaniasis is a parasitic disease that encompasses a range of clinical manifestations
affecting people in tropical and subtropical regions of the world. Epidemiological and …

Introduction Leishmaniasis is a major public health problem and the second most lethal
parasitic disease in the world due to the lack of effective treatments and vaccines. Even …

Several species of Leishmania cause human diseases that range from self-healing
cutaneous lesions to fatal visceral leishmaniasis, mucosal leishmaniasis and diffuse …

Human vaccination against leishmaniasis using live Leishmania was used in Middle East
and Russia (1941–1980). First-generation vaccines, composed by killed parasites induce …

Leishmaniasis is a diverse group of clinical syndromes caused by protozoan parasites of the
genus Leishmania. The clinical manifestation of the disease varies from self-limiting …

A vaccine against different forms of leishmaniasis should be feasible considering the wealth
of information on genetics and biology of the parasite, clinical and experimental immunology …

Leishmaniasis is caused by protozoan Leishmania parasites that are transmitted through
female sandfly bites. The disease is predominantly endemic to the tropics and semi-tropics …

Cutaneous leishmaniasis (CL) is a very common parasitic infection in subtropical areas
worldwide. Throughout decades, there have been challenges in vaccine design and …

To date, there are no proven vaccines against any form of leishmaniasis. The development
of live attenuated vectors shows promise in the field of Leishmania vaccination because …